Opioid Dependence Treatment Segmentation
Drug Cases (Naloxone, Buprenorphine, Methadone)
The buprenorphine segment is anticipated to hold the largest market share by the end of 2037, attributed to the high demand for these drugs in the developed market such as the US and France. In the United States, buprenorphine is approved by the Food and Drug Administration (FDA) for the treatment of opioid addiction. In 2019, more than 1.3 million buprenorphine prescriptions were issued in the United States. Moreover, the buprenorphine segment has grown in recent years as more healthcare providers recognize the benefits of MAT or medication-assisted treatment of opioid addiction.
Sales Channel (Retail Pharmacies, Online Pharmacies, Hospitals, Rehabilitation Centers)
The hospital segment is anticipated to hold the largest market share by the end of 2037. Treatment for opioid dependence is often given in hospitals, especially for individuals who need inpatient treatment or detoxification. Hospitals can also provide outpatient care and aftercare services to people who have completed inpatient care.
Our in-depth analysis of the global market includes the following segments:
|
By Drug Cases |
|
|
By Sales Channel |
|
